

# Alan Gamis

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11603787/publications.pdf>

Version: 2024-02-01

28  
papers

979  
citations

623734

14  
h-index

552781

26  
g-index

28  
all docs

28  
docs citations

28  
times ranked

1371  
citing authors

#	ARTICLE	IF	CITATIONS
1	Cytarabine dose reduction in patients with low-risk acute myeloid leukemia: A report from the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29313.	1.5	5
2	Polygenic Ara-C Response Score Identifies Pediatric Patients With Acute Myeloid Leukemia in Need of Chemotherapy Augmentation. <i>Journal of Clinical Oncology</i> , 2022, 40, 772-783.	1.6	7
3	Blood Count Recovery Following Induction Therapy for Acute Myeloid Leukemia in Children Does Not Predict Survival. <i>Cancers</i> , 2022, 14, 616.	3.7	4
4	Sorafenib in Combination With Standard Chemotherapy for Children With High Allelic Ratio <i>FLT3&lt;/i&gt;/ITD+ Acute Myeloid Leukemia: A Report From the Children's Oncology Group Protocol AAML1031. <i>Journal of Clinical Oncology</i>, 2022, 40, 2023-2035.</i>	1.6	36
5	A ten-gene DNA-damage response pathway gene expression signature predicts gemtuzumab ozogamicin response in pediatric AML patients treated on COG AAML0531 and AAML03P1 trials. <i>Leukemia</i> , 2022, 36, 2022-2031.	7.2	6
6	Hematopoietic Cell Transplantation in the Treatment of Pediatric Acute Myelogenous Leukemia and Myelodysplastic Syndromes: Guidelines from the American Society of Transplantation and Cellular Therapy. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 530-545.	1.2	12
7	Survival Following Relapse in Children with Acute Myeloid Leukemia: A Report from AML-BFM and COG. <i>Cancers</i> , 2021, 13, 2336.	3.7	30
8	High-dose AraC is essential for the treatment of ML-DS independent of postinduction MRD: results of the COG AAML1531 trial. <i>Blood</i> , 2021, 138, 2337-2346.	1.4	16
9	Bortezomib with standard chemotherapy for children with acute myeloid leukemia does not improve treatment outcomes: a report from the Children's Oncology Group. <i>Haematologica</i> , 2020, 105, 1879-1886.	3.5	83
10	Occurrence of Treatment-Related Cardiotoxicity and Its Impact on Outcomes Among Children Treated in the AAML0531 Clinical Trial: A Report From the Children's Oncology Group. <i>Journal of Clinical Oncology</i> , 2019, 37, 12-21.	1.6	66
11	MicroRNA Expression-Based Model Indicates Event-Free Survival in Pediatric Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2017, 35, 3964-3977.	1.6	49
12	Early discharge as a mediator of greater ICU-level care requirements in patients not enrolled on the AAML0531 clinical trial: a Children's Oncology Group report. <i>Cancer Medicine</i> , 2016, 5, 2412-2416.	2.8	4
13	Comparison of administrative/billing data to expected protocol-mandated chemotherapy exposure in children with acute myeloid leukemia: A report from the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2015, 62, 1184-1189.	1.5	12
14	Comparison of in-patient costs for children treated on the AAML0531 clinical trial: A report from the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2015, 62, 1775-1781.	1.5	21
15	Merging Children's Oncology Group Data with an External Administrative Database Using Indirect Patient Identifiers: A Report from the Children's Oncology Group. <i>PLoS ONE</i> , 2015, 10, e0143480.	2.5	16
16	Gene Expression Profiling to Predict Viridans Group Streptococcal and Invasive Fungal Infection in Pediatric Acute Myeloid Leukemia: A Brief Report from the Children's Oncology Group. <i>Acta Haematologica</i> , 2014, 131, 167-169.	1.4	4
17	Clinical Significance of CD33 Nonsynonymous Single-Nucleotide Polymorphisms in Pediatric Patients with Acute Myeloid Leukemia Treated with Gemtuzumab-Ozogamicin-Containing Chemotherapy. <i>Clinical Cancer Research</i> , 2013, 19, 1620-1627.	7.0	58
18	Development and validation of a single-cell network profiling assay-based classifier to predict response to induction therapy in paediatric patients with <i>de novo</i> acute myeloid leukaemia: a report from the Children's Oncology Group. <i>British Journal of Haematology</i> , 2013, 162, 250-262.	2.5	15

#	ARTICLE	IF	CITATIONS
19	Differences in outcomes of newly diagnosed acute myeloid leukemia for adolescent/young adult and younger patients. <i>Cancer</i> , 2013, 119, 4162-4169.	4.1	66
20	Life-threatening and Fatal Infections in Children With Acute Myeloid Leukemia. <i>Journal of Pediatric Hematology/Oncology</i> , 2012, 34, e30-e35.	0.6	29
21	Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML. <i>Blood</i> , 2012, 119, 3705-3711.	1.4	91
22	AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia. <i>Cancer</i> , 2012, 118, 761-769.	4.1	157
23	Infections and association with different intensity of chemotherapy in children with acute myeloid leukemia. <i>Cancer</i> , 2009, 115, 1100-1108.	4.1	101
24	COG AAML03P1: Efficacy and Safety in a Pilot Study of Intensive Chemotherapy Including Gemtuzumab in Children Newly Diagnosed with Acute Myeloid Leukemia (AML). <i>Blood</i> , 2008, 112, 136-136.	1.4	10
25	Correlation of CD 33 Expression Level with Disease Characteristics and Response to Gemtuzumab Ozogamycin-Containing Chemotherapy in Childhood AML. <i>Blood</i> , 2008, 112, 148-148.	1.4	1
26	Functional Polymorphisms in Oxidant Metabolism and DNA Repair Pathways and Risk of Leukemia and Transient Myeloproliferative Disorder in Children with Down Syndrome. <i>Blood</i> , 2008, 112, 2947-2947.	1.4	0
27	Cyclosporine, Interferon- $\gamma$ , and Interleukin-2 Immunotherapy Is Tolerable and Induces Autoreactivity in Patients with Recurrent/Refractory Hodgkin Disease Undergoing Autologous Stem Cell Transplantation with BEAM: A COG Study. <i>Blood</i> , 2005, 106, 2087-2087.	1.4	0
28	Mitoxantrone and Cytarabine Induction, High-Dose Cytarabine, and Etoposide Intensification for Pediatric Patients With Relapsed or Refractory Acute Myeloid Leukemia: Children's Cancer Group Study 2951. <i>Journal of Clinical Oncology</i> , 2003, 21, 2940-2947.	1.6	80